Log in to search using one of your social media accounts:

 

Bath Psoralen-ultraviolet A and Narrowband Ultraviolet B Phototherapy as Initial Therapy for Early-stage Mycosis Fungoides: A Retrospective Cohort of 267 Cases at the University of Toronto
Phototherapy is one of the mainstay treatments for early stages mycosis fungoides (MF). Response rates are not statistically different when utilizing either bath PUVA or nbUVB in early stage MF. However, longer remission is achieved with bath PUVA therapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 19, 2017 Category: Hematology Authors: Mohammad Almohideb, Sandra Walsh, Scott Walsh, Neil Shear, Raed Alhusayen Tags: Original Study Source Type: research

Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study
Chemotherapy-induced nausea and vomiting (CINV) is common in patients who receive high-dose melphalan as a conditioning regimen before autologous hematopoietic stem cell transplantation. With suboptimal CINV control using an aprepitant-based antiemetic regimen, we switched to an olanzapine-based regimen. We performed a retrospective study to compare these 2 regimens and found significant improvement in acute and delayed nausea control and a reduction in the use of CINV rescue medications. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 19, 2017 Category: Hematology Authors: Steven Trifilio, Colleen Welles, Kristin Seeger, Shivani Mehta, MaryAnne Fishman, Katherine McGowan, Kathryn Strejcek, Emily Eiten, Carolyn Pirotte, Elizabeth Lucier, Sean DeFrates, Jayesh Mehta Tags: Original Study Source Type: research

Olanzapine reduces chemotherapy induced nausea and vomiting compared to aprepitant in myeloma patients receiving high-dose melphalan prior to stem cell transplantation: A retrospective study
Chemotherapy induced nausea and vomiting (CINV) is common in patients who receive high-dose melphalan as conditioning regimen prior to autologous hematopoetic stem cell transplantation. With sub-optimal CINV control with an aprepitant based antiemetic regimen, we changed to an olanzapine based regimen. A retrospective study which compared these two regimens showed significant improvement in acute and delayed nausea control and reduction in CINV rescue medications. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 19, 2017 Category: Hematology Authors: Steven Trifilio, Colleen Welles, Kristin Seeger, Shivani Mehta, MaryAnne Fishman, Katherine McGowan, Kathryn Strejcek, Emily Eiten, Carolyn Pirotte, Elizabeth Lucier, Sean DeFrates, Jayesh Mehta Tags: Original Study Source Type: research

Bath Psoralen-Ultraviolet A and Narrow-Band Ultraviolet B Phototherapy as Initial Therapy in Early Stage Mycosis Fungoides: A Retrospective Cohort of 267 Cases Seen at the University of Toronto
Phototherapy is one of the mainstay treatments for early stages mycosis fungoides (MF). Response rates are not statistically different when utilizing either bath PUVA or nbUVB in early stage MF. Longer remission is achieved with bath PUVA therapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 19, 2017 Category: Hematology Authors: Mohammad Almohideb, Sandra Walsh, Scott Walsh, Neil Shear, Raed Alhusayen Tags: Original Study Source Type: research

FLAG-Ida regimen as bridge therapy to allotransplant in refractory/relapsed AML patients
Primary refractory/first relapse AML patients are considered to have a worse clinical outcome post-treatment. For these patients the achievement of CR appears to be crucial in order to be able to undergo allotransplantation, maybe the only possible treatment. We used the FLAG-Ida regimen in this kind of patients as a bridge to transplant, and studied its efficacy in terms of overall response (OR) and survival (OS) rates, to assess which variables (age, LDH, bone marrow (BM), peripheral blood (PB) blasts and platelets counts, white blood cells (WBC), de novo or secondary AML, molecular-cytogentic risk, duration of response ...
Source: Clinical Lymphoma, Myeloma and Leukemia - June 19, 2017 Category: Hematology Authors: Mario Delia, Domenico Pastore, Paola Carluccio, Crescenza Pasciolla, Alessandra Ricco, Antonella Russo Rossi, Paola Casieri, Anna Mestice, Francesco Albano, Giorgina Specchia Tags: Original Study Source Type: research

TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
Allogeneic hematopoietic cell transplantation represents the only treatment option capable of offering a cure to patients with myelodysplastic syndrome. Here, we demonstrate that presence of mutations in TP53 and IDH2 in myelodysplastic syndrome confer a poor prognosis even in the setting of allogeneic transplantation. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 16, 2017 Category: Hematology Authors: Mohamed A. Kharfan-Dabaja, Rami S. Komrokji, Qing Zhang, Ambuj Kumar, Athanasios Tsalatsanis, Janelle Perkins, Taiga Nishihori, Teresa Field, Najla Al Ali, Asmita Mishra, David Sallman, Karma Z. Salem, Ling Zhang, Lynn Moscinski, Hugo F. Fernandez, Jeffre Tags: Original Study Source Type: research

Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma
We explored safety and efficacy of the combination of pharmacokinetics-directed busulfan, melphalan and bortezomib as conditioning regimen for autologous stem cell transplantation in multiple myeloma. In this prospective phase II trial, 19 patients were treated and achieved an overall response rate of 100% and a 2-year progression-free survival and overall survival of 57.9% and 88.5% respectively with acceptable toxicities. This suggests the combination is effective and safe. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 16, 2017 Category: Hematology Authors: Stefan K. Barta, Rishi Jain, Amithaba Mazumder, Jason Carter, Lawrence Almanzar, Roy Browne, Samira Shahnaz, Richard Elkind, David Kaminetzky, Ramakrishna Battini, Olga Derman, Noah Kornblum, Amit Verma, Ira Braunschweig Tags: Original Study Source Type: research

Baseline characteristics predicting very good outcome of allogeneic Hematopoietic Cell Transplantation in young high cytogenetic risk Chronic Lymphocytic Leukemia patients - a retrospective analysis from the Chronic Malignancies Working Party of the EBMT
CLL patients with del(17p) or del(11q) have poor long-term prognosis with targeted therapies. Conversely, this retrospective EBMT registry study shows that young high cytogenetic risk responsive patients with HLA-matched donors have a high 8-year progression-free-survival and low 2-year non-relapse mortality after allogeneic stem cell transplantation. This treatment then may compare favorably with targeted therapies for younger high cytogenetic risk patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 16, 2017 Category: Hematology Authors: Michel van Gelder, Dimitris Ziagkos, Liesbeth de Wreede, Anja van Biezen, Peter Dreger, Martin Gramatzki, Matthias Stelljes, Niels Smedegaard Andersen, Nicolaas Schaap, Antonin Vitek, Dietrich Beelen, Vesa Lindstr öm, Jürgen Finke, Jacob Passweg, Matthi Tags: Original Study Source Type: research

PK-directed Intravenous Busulfan in Combination with High-Dose Melphalan and Bortezomib as a Conditioning Regimen for Patients with Multiple Myeloma
High dose chemotherapy followed by autologous stem cell transplantation (ASCT) has a well-established role in the treatment of patients with multiple myeloma. Melphalan 200 mg/m2 (Mel200) is the most commonly used preparative regimen. Several studies have provided evidence for potential synergism and safety when combining bortezomib (Btz) or busulfan (Bu) with melphalan (Mel). We conducted a prospective phase 2 study to investigate the safety and efficacy of conditioning with PK directed intravenous (IV) Bu with Btz and Mel. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 16, 2017 Category: Hematology Authors: Stefan K. Barta, Rishi Jain, Amithaba Mazumder, Jason Carter, Lawrence Almanzar, Roy Browne, Samira Shahnaz, Richard Elkind, David Kaminetzky, Ramakrishna Battini, Olga Derman, Noah Kornblum, Amit Verma, Ira Braunschweig Tags: Original Study Source Type: research

Utility of Bone Marrow Biopsy and Aspirate for Staging of Diffuse Large B Cell Lymphoma in the Era of Positron Emission Tomography with 2-Deoxy-2-[Fluorine-18]Fluoro-D-Glucose Integrated with Computed Tomography
About one-third of patients with diffuse large B cell lymphoma (DLBCL) have lymphomatous bone marrow involvement (BMI) at the time of diagnosis, and bone marrow aspirate/biopsy (BMAB) is considered the gold standard to detect such involvement. [18F] fluorodeoxyglucose (FDG) positron emission tomography combined with computed tomography (PET-CT), has become standard pre-treatment imaging in DLBCL and may be a noninvasive alternative to BMAB to ascertain BMI. Prior studies have suggested that PET-CT scan may obviate the need for BMAB as a component for staging patients with newly diagnosed DLBCL, but this is not yet a standa...
Source: Clinical Lymphoma, Myeloma and Leukemia - June 16, 2017 Category: Hematology Authors: Prakash Vishnu, Andrew Wingerson, Marie Lee, Margaret T. Mandelson, David M. Aboulafia Tags: Original Study Source Type: research

Effects of bosutinib treatment on renal function in patients with Philadelphia chromosome-positive leukemias
We evaluated incidence of renal adverse events and estimated glomerular filtration rate in patients with Philadelphia chromosome-positive leukemias receiving first-line bosutinib (n=248) or imatinib (n=251), or second-line or later bosutinib (N=570). Results demonstrate that long-term bosutinib treatment is associated with an apparently reversible decline in renal function with frequency and characteristics similar to those observed with long-term imatinib. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 16, 2017 Category: Hematology Authors: Jorge E. Cortes, Carlo Gambacorti-Passerini, Dong-Wook Kim, Hagop M. Kantarjian, Jeff H. Lipton, Amit Lahoti, Moshe Talpaz, Ewa Matczak, Elly Barry, Eric Leip, Tim H. Br ümmendorf, H. Jean Khoury Tags: Original Study Source Type: research

TP53 and IDH2 somatic mutations are associated with inferior overall survival following allogeneic hematopoietic cell transplantation for myelodysplastic syndrome
Next generation sequencing has identified somatic mutations that are prognostic of cancer. We evaluated the incidence and prognostic significance of somatic mutations in 89 MDS patients who received an allogeneic hematopoietic cell transplant. Next generation sequencing was performed on paraffin embedded bone marrow which was obtained at a median of 31 days prior to initiating the preparative regimen. The 3 most common subtypes of MDS were RAEB-1 (35%), RAEB-2 (29%) and RCMD (18%). Most patients (n=91%) received a myeloablative regimen of fludarabine plus intravenous busulfan. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 16, 2017 Category: Hematology Authors: Mohamed A. Kharfan-Dabaja, Rami S. Komrokji, Qing Zhang, Ambuj Kumar, Athanasios Tsalatsanis, Janelle Perkins, Taiga Nishihori, Teresa Field, Najla Al Ali, Asmita Mishra, David Sallman, Karma Z. Salem, Ling Zhang, Lynn Moscinski, Hugo F. Fernandez, Jeffre Tags: Original Study Source Type: research

Age acts as an adverse independent variable for survival in acute lymphoblastic leukemia: Data from a cohort in Northeast Mexico
Acute lymphoblastic leukemia is a highly heterogeneous disease whose clinical course and outcome are strongly influenced by age. A cohort including 377 patients of all ages from a low-middle income and homogeneous population receiving standardized treatment protocols over a decade was analyzed. Age 20 years was significantly associated with lower overall survival. Infants fared worst. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 16, 2017 Category: Hematology Authors: Jos é Carlos Jaime-Pérez, Lucía Teresa Fernández, Raúl Alberto Jiménez-Castillo, Andrés Gómez-De León, Olga Graciela Cantú-Rodríguez, César Homero Gutiérrez-Aguirre, David Gómez-Almaguer Tags: Original Study Source Type: research

Elevated Cardiovascular Disease Risk in Patients With Chronic Myelogenous Leukemia Seen in Community-based Oncology Practices in the United States
Guidelines recommend that comorbidities, including CVD, be considered when selecting TKIs for the treatment of CML. An increased risk of CVD and its risk factors in CML patients treated by community-based US oncologists was identified in a real-world analysis of an EMR database (N=1,639). These results underscore the importance of current NCCN ® recommendations to consider CV risk when selecting TKIs. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 16, 2017 Category: Hematology Authors: Anna D. Coutinho, Dinara Makenbaeva, Eileen Farrelly, Pamela B. Landsman-Blumberg, Daniel Lenihan Tags: Original Study Source Type: research

Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes
This study provides insight into potential modifications of standard eligibility criteria that can lead to improved trial design. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 16, 2017 Category: Hematology Authors: Jatin J. Shah, Rafat Abonour, Christina Gasparetto, James W. Hardin, Kathleen Toomey, Mohit Narang, Shankar Srinivasan, Amani Kitali, Faiza Zafar, E. Dawn Flick, Robert M. Rifkin Tags: Original Study Source Type: research

Immuno-oncologic approaches: CAR-T cells and checkpoint inhibitors
Advances in understanding the myeloma biology have shown that disease progression is not only the consequence of intrinsic tumor changes but also of interactions between the tumor and the microenvironment in which the cancer grows. Immune system is an important component of the tumor microenvironment in myeloma, and acting on immune system is an appealing new treatment strategy. There are 2 ways to act towards immune cells and boost anti-tumor immunity: 1) to increase antitumor activity (acting on T and NK cytotoxic cells); and 2) to reduce immunosuppression (acting on myeloid-derived stem-cells and T regulatory cells). (S...
Source: Clinical Lymphoma, Myeloma and Leukemia - June 16, 2017 Category: Hematology Authors: Francesca Gay, Mattia D ’Agostino, Luisa Giaccone, Mariella Genuardi, Moreno Festuccia, Mario Boccadoro, Benedetto Bruno Tags: Review Article Source Type: research

Rituximab Improves the Outcome of Patients with Grade 3 Follicular Lymphoma Receiving Anthracycline-based Therapy
The addition of rituximab to chemotherapy has improved the outcome of patients with follicular lymphoma (FL). However, data on grade 3 FL (FL3) and its subtypes are lacking. The aims of the study were to determine: 1) the clinical features and outcome of patients with FL3 treated with rituximab and anthracycline-based chemotherapy; and 2) the clinical significance of the three subtypes of FL3. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 16, 2017 Category: Hematology Authors: Ji Yuan, Timothy C. Greiner, Kai Fu, Lynette M. Smith, Patricia Aoun, Wing C. Chan, Philip J. Bierman, Robert G. Bociek, Julie M. Vose, James O. Armitage, Dennis D. Weisenburger Tags: Original Study Source Type: research

Primary Amyloidosis with Renal Involvement: Outcomes in 77 Consecutive Patients at a Single Center
Outcomes in primary amyloid renal patients are of interest as the era of monoclonal antibody therapies begins. We studied 77 consecutive primary amyloid renal patients (58% men) for renal progression (ESRD), renal response (RR) and overall survival (OS). At diagnosis median age was 63 (range, 35-81), eGFR 70ml/min (5-114), dFLC 127mg/L (1-9957), ESRD 4%, renal stage 2 and 3 78%, and cardiac stage 2 and 3 56%. Ninety-six percent received bortezomib and 44% both stem cell transplant (SCT) and bortezomib, 68% achieved complete or very good partial hematologic responses (CR/VGPR), 34% had ESRD and 39% RR. (Source: Clinical Lym...
Source: Clinical Lymphoma, Myeloma and Leukemia - June 16, 2017 Category: Hematology Authors: Sandy W. Wong, Denis Toskic, Melissa Warner, Cindy Varga, Alejandro Moreno-koehler, Daniel Fein, Teresa Fogaren, Lisa Lee, Colin M. Oliver, Spencer D. Guthrie, Raymond L. Comenzo Tags: Original Study Source Type: research

Autologous Stem Cell Transplantation in Patients With Multiple Myeloma: An Activity-based Costing Analysis, Comparing a Total Inpatient Model Versus an Early Discharge Model
We calculated the cost of autologous stem cell transplantation in multiple myeloma using the activity-based costing method, through two different care model: total inpatient program (TIM) and Early-Discharge Outpatient Model (EDOM). TIM and EDOM models involved a total cost of €28.615,15 and €16.499,43. The repayment of the diagnosis-related group (DRG) in Italy is approximately €50.000 and it does not correspond to the real cost of the procedure. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 6, 2017 Category: Hematology Authors: Massimo Martino, Giuseppe Console, Letteria Russo, Antonella Meliado', Nicola Meliambro, Tiziana Moscato, Giuseppe Irrera, Giuseppe Messina, Antonella Pontari, Fortunato Morabito Tags: Original Study Source Type: research

Autologous stem cell transplantation in Multiple Myeloma patients: an activity-based costing analysis, comparing a Total Impatient Model versus an Early Discharge Model
Activity-based costing (ABC) was developed and advocated as a means of overcoming the systematic distortions of traditional cost accounting. We calculated the cost of High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Multiple Myeloma patients using the ABC method, through two different care model: Total Inpatient Model (TIM) and Early-Discharge Outpatient Model (EDOM) and compared it with the approved Diagnosis Related Groups (DRG) Italian tariffs. TIM and EDOM models involved a total cost of € 28.615,15 and € 16.499,43, respectively. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 6, 2017 Category: Hematology Authors: Massimo Martino, Giuseppe Console, Letteria Russo, Antonella Meliado ’, Roberta Fedele, Tiziana Moscato, Giuseppe Irrera, Giuseppe Messina, Antonella Pontari, Fortunato Morabito Source Type: research

Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and S ézary Syndrome
Mycosis fungoides and S ézary syndrome (MF/SS) management is complex, with heterogeneous treatments. The authors analyzed a national registry of over 2,200 MF/SS patients divided into cohorts by annual treatment volume (ATV) quintile of their treatment facility. Higher facility annual treatment volume was associated with improved survival for patients with MF/SS. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 6, 2017 Category: Hematology Authors: Benjamin H. Kann, Henry S. Park, Debra N. Yeboa, Sanjay Aneja, Michael Girardi, Francine M. Foss, Kenneth B. Roberts, Lynn D. Wilson Source Type: research

Prognostic factors and outcomes of adult lymphoblastic lymphoma in the United States
We retrieved data of 696 adult patients with lymphoblastic lymphoma (LL) from the SEER-18 registries (53% T-LL, 19% B-LL). Five year survival rates for B-LL and T-LL were similar (45% vs. 48%). Age, race and radiotherapy were independent prognostic factors for outcome in T-LL. Limited tumor stage, and the most recent year of diagnosis are favorable prognostic factors for B-LL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 6, 2017 Category: Hematology Authors: Mohamed Abd El-Fattah Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 1, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 1, 2017 Category: Hematology Source Type: research

A Phase I/II Trial of Panobinostat in Combination with Lenalidomide in Patients with Relapsed or Refractory Hodgkin Lymphoma
Based on previous studies demonstrating single agent efficacy with lenalidomide and panobinostat in patients with relapsed or refractory Hodgkin lymphoma (HL), we conducted a phase I/II study to evaluate the safety and efficacy of the combination in this patient population. The recommended phase 2 dose was 25 mg lenalidomide days 1-21 with 15 mg panobinostat TIW, and an ORR of 16.7% in patients was observed, with a durable response in one patient with lymphocyte predominant HL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 22, 2017 Category: Hematology Authors: Joseph J. Maly, Beth A. Christian, Xiaohua Zhu, Lai Wei, Jennifer L. Sexton, Samantha M. Jaglowski, Steven M. Devine, Todd A. Fehniger, Nina D. Wagner-Johnston, Mitch A. Phelps, Nancy L. Bartlett, Kristie A. Blum Source Type: research

Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation
Surveillance imaging is often used following autologous hematopoietic cell transplantation (auto-HCT) to assess for relapse. We evaluated classical Hodgkin lymphoma (cHL) patients who received auto-HCT, achieved  complete remission, and underwent surveillance imaging. Relapse was detected clinically or by surveillance imaging. Outcomes were similar between the two groups. There appears to be limited utility for surveillance imaging in cHL after auto-HCT. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 12, 2017 Category: Hematology Authors: Jonathan T. Kapke, Narendranath Epperla, Namrata Shah, Kristin Richardson, George Carrum, Parameswaran N. Hari, Sai R. Pingali, Mehdi Hamadani, Reem Karmali, Timothy S. Fenske Tags: Original Study Source Type: research

Impact of routine surveillance imaging on the outcomes of patients with classical Hodgkin lymphoma following autologous hematopoietic cell transplantation
Patients with relapsed and refractory classical Hodgkin lymphoma (cHL) are often treated with autologous hematopoietic cell transplantation (auto-HCT). After auto-HCT, most transplant centers implement routine surveillance imaging to monitor for disease relapse; however, there is limited evidence to support this practice. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 12, 2017 Category: Hematology Authors: Jonathan T. Kapke, Narendranath Epperla, Namrata Shah, Kristin Richardson, George Carrum, Parameswaran N. Hari, Sai R. Pingali, Mehdi Hamadani, Reem Karmali, Timothy S. Fenske Source Type: research

Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I
Ruxolitinib provided clinical benefit for patients with myelofibrosis in clinical trials. However, assessing benefit in community settings remains challenging. This exploratory analysis evaluated results from the phase 3 COMFORT-I trial using practical measures (N=286). Spleen length alone was insufficient for identifying all patients receiving clinical benefit, emphasizing the importance of using multiple myelofibrosis assessment methods in the community setting. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 12, 2017 Category: Hematology Authors: Carole B. Miller, Rami S. Komrokji, Ruben A. Mesa, William Sun, Michael Montgomery, Srdan Verstovsek Source Type: research

Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma
We evaluated the combination of pegylated liposomal doxorubicin, bortezomib and vorinostat in 32 patients with relapsed/refractory multiple myeloma in a phase I study. The maximum tolerated dose of vorinostat with PLD/bortezomib was 400 mg on days 4 to 11. Clinical activity was seen including in bortezomib-refractory patients. However, hematologic, constitutional and gastrointestinal toxicity was common. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 10, 2017 Category: Hematology Authors: Peter M. Voorhees, Cristina Gasparetto, Dominic T. Moore, Diane Winans, Robert Z. Orlowski, David D. Hurd Tags: Original Study Source Type: research

Outcome and Clinical Significance of Immunophenotypic Markers Expressed in Different Treatment Protocols of Pediatric Patients With T-ALL in Developing Countries
This study aimed to evaluate pediatric patients had T-cell acute lymphoblastic leukemia (T-ALL) at two different Arabic cancer centers regarding their clinic-pathologic, immunophenotypic and cytogenetic features and outcome. Study included 103 patients with median age of 8.9 years. Male to female ratio was 2.6:1. Patients divided into (group I) treated with BFM-90 treatment protocol between February 2003 and June 2007 and (group II) includes all patients treated thereafter by the total therapy study XIII protocol for high-risk ALL. Outcome of patients with T-ALL significantly improved in patients received treatment protoco...
Source: Clinical Lymphoma, Myeloma and Leukemia - May 10, 2017 Category: Hematology Authors: Douaa M. Sayed, Heba Abdel Razik Sayed, Heba N. Raslan, Amany M. Ali, Asmaa Zahran, Reema Al-Hayek, Saad A. Daama, Arwa Al-Saber Tags: Original Study Source Type: research

Impact of Health Care Insurance Status on Treatment Outcomes of Acute Myeloid Leukemia
Insurance status has been found to influence treatment outcomes in various solid tumors, but limited data is available for patients with acute myeloid leukemia (AML). A total of 161 patients were included in this retrospective study to examine the impact of insurance source in AML outcomes in the state of Oklahoma. Insurance source at diagnosis was found to have no impact on AML treatment outcomes and receipt of bone marrow transplant. The consistency of our results with some, but not all, studies is probably driven primarily by access-to-care requirements among different states. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 10, 2017 Category: Hematology Authors: Samer A. Srour, Michael Machiorlatti, Namali T. Pierson, Usman Z. Bhutta, Mohamad Cherry, George B. Selby, David M. Thompson, Sara K. Vesely, Carla D. Kurkjian Tags: Original Study Source Type: research

ZOH é: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated With Chemotherapy for Lymphoid Malignancies
The ZOH é study showed that Zarzio is readily used for prophylaxis of chemotherapy-induced neutropenia in France, and clinicians' assessment of febrile neutropenia risk is driven by patient factors more than the EORTC risk category of the chemotherapy regimen. Maintenance of dose intensity was high, especi ally in patients with non-Hodgkin lymphoma at high risk of neutropenia. Zarzio safety profile was confirmed. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 10, 2017 Category: Hematology Authors: Gandhi Laurent Damaj, Omar Benbrahim, Maya Hacini, Inna Voronina, Khaled Benabed, Ravaka-Fatoma Soumoudronga, Isabelle Gasnereau, Corinne Haioun, Philippe Solal-C éligny Tags: Original Study Source Type: research

Viral-induced hemorrhagic cystitis after allogeneic hematopoietic stem cell transplant
Hemorrhagic cystitis (HC) is a well-recognized problem that is regularly observed after hematopoietic stem cell transplantation (HSCT). The published data does not report on the potential risk factors for the viral-induced HC that might require prophylactic treatments. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 10, 2017 Category: Hematology Authors: Gilles Dosin, Fouad Aoun, Elie El Rassy, Tarek Assi, Philippe Lewalle, Jeremy Blanc, Roland van Velthoven, Dominique Bron Source Type: research

Expression of peripheral blood miRNA-720 and miRNA-1246 can be used as a predictor for outcome in multiple myeloma patients.
Multiple myeloma(MM) is a heterogeneous disorder, encompassing several related entities that share the common characteristic of being composed of monoclonal plasma cells (PCs). MicroRNAs (miRNAs) are small non-coding RNAs that control the expression of many target messenger RNAs involved in normal cell functions. Two serum microRNAs, miRNA-720 and miRNA-1246, were found to have potential as diagnostic biomarkers in myeloma. Therefore, we investigated a possible correlation of peripheral blood(PB) miRNAs expression with diagnosis, and prognosis. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 10, 2017 Category: Hematology Authors: Yuyue Ren, Xiaoyun Li, Wei Wang, Wanting He, Jinghua Wang, Ying Wang Source Type: research

“Outcome and Clinical Significance of Immunophenotypic Markers Expressed in different treatment protocols of T-ALL Pediatric Patients in developing countries
This study aimed to evaluate pediatric patients had T-ALL at two different Arabic cancer centers regarding their clinic-pathologic, immunophenotypic and cytogenetic features and outcome. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 10, 2017 Category: Hematology Authors: Douaa M. Sayed, Heba Abdel Razik Sayed, Heba N. Raslan, Amany M. Ali, Asmaa Zahran, Reema Al-Hayek, Saad A. Daama, Arwa Al-Saber Source Type: research

A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)
The CHAMPION-2 study evaluated 3 dose levels of carfilzomib when given with fixed dose oral cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma. Carfilzomib with cyclophosphamide and dexamethasone is effective and has manageable toxicity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 10, 2017 Category: Hematology Authors: Ralph V. Boccia, Alberto Bessudo, Richy Agajanian, Paul Conkling, Wael Harb, Hui Yang, Dawn Pinchasik, Amy S. Kimball, James R. Berenson Source Type: research

Final results of a phase I study of vorinostat, pegylated liposomal doxorubicin and bortezomib in relapsed or refractory multiple myeloma
Deacetylase inhibitors have synergistic activity in combination with proteasome inhibitors and anthracyclines in preclinical models of multiple myeloma. We therefore evaluated the safety and efficacy of the deacetylase inhibitor vorinostat in combination with pegylated liposomal doxorubicin (PLD) and bortezomib in relapsed/refractory multiple myeloma. Thirty-two patients were treated with PLD and bortezomib in combination with escalating doses of vorinostat on days 4 – 11 or 1 – 14. The maximum tolerated dose of vorinostat was 400 mg on days 4 – 11. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 10, 2017 Category: Hematology Authors: Peter M. Voorhees, Cristina Gasparetto, Dominic T. Moore, Diane Winans, Robert Z. Orlowski, David D. Hurd Source Type: research

Impact of Healthcare Insurance Status on Treatment Outcomes of Acute Myeloid Leukemia
We examined the impact of health insurance at diagnosis on AML treatment outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 10, 2017 Category: Hematology Authors: Samer A. Srour, Michael Machiorlatti, Namali T. Pierson, Usman Z. Bhutta, Mohamad Cherry, George B. Selby, David M. Thompson, Sara K. Veseley, Carla D. Kurkjian Source Type: research

Generic Imatinib in Chronic Myeloid Leukemia: Survival of the cheapest
The results of a retrospective analysis, of data from a large group patients with chronic myeloid leukemia (CML) treated with frontline Imatinib mesylate (Innovator/Generic) at a single institution between 2008 and 2014 showed comparable efficacy and safety. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 10, 2017 Category: Hematology Authors: Madhav Danthala, Sadashivudu Gundeti, Siva Prasad Kuruva, Krishna Chaitanya Puligundla, Praveen Adusumilli, Ashok Pillai Karnam, Stalin Bala, Meher Lakshmi Konatam, Lakshmi Srinivas Maddali, Raghunadha Rao Digumarti Source Type: research

ZOH é: A prospective study of the use of biosimilar filgrastim Zarzio® in clinical practice in patients treated with chemotherapy for lymphoid malignancies
The ZOH é study showed that Zarzio® is readily used for prophylaxis of chemotherapy-induced neutropenia in France, and clinicians’ assessment of febrile neutropenia risk is driven by patient factors more than the EORTC risk category of the chemotherapy regimen. Maintenance of dose intensity was high, es pecially in non-Hodgkin lymphoma patients at high risk of neutropenia. Zarzio® safety profile was confirmed. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 10, 2017 Category: Hematology Authors: Gandhi Laurent Damaj, Omar Benbrahim, Maya Hacini, Inna Voronina, Khaled Benabed, Ravaka-Fatoma Soumoudronga, Isabelle Gasnereau, Corinne Haioun, Philippe Solal-C éligny Source Type: research

Metabolic Syndrome in Long-Term Survivors of Hematopoietic Stem-Cell Transplantation
Since its introduction more than 50 years ago, hematopoietic stem-cell transplantation (HSCT) has transformed from an inescapably fatal procedure to one where cure from malignant and other nonmalignant hematologic diseases is becoming increasingly common. Nevertheless, longevity is not entirely restored. New causes of mortality have emerged; of particular importance is that of increased cardiovascular disease (CVD), related to metabolic syndrome and its components. Controversy exists over whether the metabolic abnormalities induced are a direct effect of HSCT itself or a consequence of other therapies involved. (Source: Cl...
Source: Clinical Lymphoma, Myeloma and Leukemia - May 9, 2017 Category: Hematology Authors: Sophie C. Ragbourne, Martin A. Crook Tags: Review Source Type: research

New Agents in Multiple Myeloma: An  Examination of Safety Profiles
Numerous treatments are available for relapsed and/or refractory multiple myeloma (MM), with safety profiles varying across drug classes and across agents within the same class. Thus, it is important to understand the toxicities of each antimyeloma agent when making treatment decisions. Neutropenia is commonly associated with lenalidomide and pomalidomide, and may be common with histone deacetylase (HDAC) inhibitors, but is relatively unusual with thalidomide, bortezomib, and carfilzomib. Infection was common in trials of lenalidomide and pomalidomide, and upper respiratory tract infection and pneumonia have been seen with...
Source: Clinical Lymphoma, Myeloma and Leukemia - May 9, 2017 Category: Hematology Authors: Sara Bringhen, Edwin De Wit, Meletios-Athanassios Dimopoulos Tags: Review Source Type: research

New Agents in Multiple Myeloma: An Examination of Safety Profiles
Numerous treatments are available for relapsed and/or refractory multiple myeloma (MM), with safety profiles varying across drug classes and across agents within the same class. Thus, it is important to understand the toxicities of each antimyeloma agent when making treatment decisions. Neutropenia is commonly associated with lenalidomide and pomalidomide, and may be common with histone deacetylase (HDAC) inhibitors, but is relatively unusual with thalidomide, bortezomib and carfilzomib. Infection was common in trials of lenalidomide and pomalidomide, and upper respiratory tract infection and pneumonia have been seen with ...
Source: Clinical Lymphoma, Myeloma and Leukemia - May 9, 2017 Category: Hematology Authors: Sara Bringhen, Edwin De Wit, Meletios-Athanassios Dimopoulos Tags: Review Article Source Type: research

Treatment of Peripheral T-Cell Lymphoma in Community Settings
Peripheral T-cell lymphomas (PTCLs) represent a rare and heterogeneous group of malignancies which do not have consensus treatment recommendations. This retrospective review of 93 patients treated in community settings demonstrated considerable variability in treatment strategies. First-line CHOP and CHOP-like regimens were used in 74% of patients, providing 4-year overall survival outcomes of 34% in patients without transplant consolidation and 77% with transplantation. . (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 9, 2017 Category: Hematology Authors: Tatyana Feldman, Charles M. Farber, Kelly Choi, Claudio Faria, Andre Goy, Jacqueline Connors, Dhakshila Paramanathan, Sukhi Kaur, Eric Schultz, Michael McGuire, Stuart L. Goldberg Source Type: research

The Metabolic Syndrome in long-term survivors of Haematopoietic Stem Cell Transplantation
Since its introduction more than fifty years ago, haematopoietic stem cell transplantation (HSCT) has transformed from an inescapably fatal procedure to one where cure from malignant and other non-malignant haematological diseases is becoming increasingly common. Nevertheless, longevity is not entirely restored. New causes of mortality have emerged; of particular importance is that of increased cardiovascular disease (CVD), related to metabolic syndrome (MS) and its components. Controversy exists over whether the metabolic abnormalities induced are a direct effect of HSCT itself or a consequence of other therapies involved...
Source: Clinical Lymphoma, Myeloma and Leukemia - May 9, 2017 Category: Hematology Authors: S.C. Ragbourne, M.A. Crook Tags: Review Article Source Type: research

Chronic lymphocytic leukemia patients with deletion 11q have a short time to requirement of first-line therapy, but long overall survival: results of a population-based cohort in British Columbia, Canada
This study documents the clinical course of 67 with high-risk CLL patients with 11q- deletion, from a Provincial CLL database. Aklylator-containing chemotherapies are thought to required to overcome the adverse prognosis associated with 11q-. However, most 11q- patients did not receive alkylators first line and had a median survival of 14.7 years, comparable to the rest of the cohort. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 8, 2017 Category: Hematology Authors: Jennifer Goy, Tanya L. Gillan, Helene Bruyere, Steven J.T. Huang, Monica Hrynchak, Aly Karsan, Khaled Ramadan, Joseph Connors, Cynthia L. Toze, Alina S. Gerrie Tags: Original Study Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 29, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 29, 2017 Category: Hematology Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 1, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 1, 2017 Category: Hematology Source Type: research